Microbiome NewsIn a systematic review and meta-analysis published in the Journal of tropical pediatrics, researchers investigated the potential benefits of probiotics for critically ill children in pediatric intensive care units (PICUs). This comprehensive analysis focused on assessing the efficacy and safety of probiotics in preventing ventilator-associated pneumonia (VAP) and other critical outcomes such as all-cause mortality, length of hospital stay (LOS), and duration of mechanical ventilation (MV).
Study Design and Outcomes
The researchers conducted a systematic review of randomized controlled trials (RCTs) sourced from major databases including PubMed, EMBASE, SCOPUS, and Web of Science. The primary outcome of interest was all-cause mortality among critically ill children, while secondary outcomes included the incidence of VAP, LOS, and MV duration. In total, eight RCTs involving 744 children were included in the analysis. The researchers employed random-effects models to pool risk ratios (RR) and mean differences (MD), with the Hartung-Knapp adjustment used for sensitivity analysis. The certainty of evidence was evaluated using the GRADE approach.
Key Findings
The analysis revealed that probiotics did not significantly reduce all-cause mortality among the children studied (RR 0.85, 95% CI 0.66-1.11; P = .24; I² = 0%; low certainty). This finding remained consistent even when the analysis was restricted to low-risk-of-bias trials (RR 0.89, 0.60-1.34; P = .58). However, probiotics significantly reduced the incidence of VAP, with a risk ratio of 0.47 (95% CI 0.35-0.64; P < .0001; I² = 0%), indicating a high level of certainty. The absolute risk reduction for VAP was 21.9%, translating to a number needed to treat of approximately five children to prevent one case of pneumonia.
In terms of LOS and MV duration, probiotics did not show significant reductions. The mean difference for LOS was -2.57 days (95% CI -7.26 to 2.11; P = .20) and for MV duration was -1.61 days (95% CI -4.43 to 1.20; P = .17), both with low certainty. Importantly, no serious adverse events associated with probiotic use were reported in the trials included.
Implications and Limitations
The findings suggest that while probiotics do not significantly impact all-cause mortality or reduce hospital stay and ventilation duration, they may play a role in reducing the risk of VAP among critically ill children. This could position probiotics as a potential adjunctive strategy for VAP prevention in PICUs. However, the inconclusive results regarding mortality and other secondary outcomes highlight the need for larger, multicenter trials to further explore these potential benefits.
It is important to note the limitations of this analysis. The relatively small sample size of 744 children across eight trials may impact the generalizability of the findings. Additionally, the low certainty of evidence for mortality and secondary outcomes suggests that these results should be interpreted with caution. Further research is necessary to confirm these findings and to explore the mechanisms by which probiotics may influence health outcomes in critically ill children.
For more on the potential roles of probiotics, you might explore our article on precision probiotics.
Frequently asked
What was the primary outcome of this review?
The primary outcome of the systematic review was all-cause mortality among critically ill children in pediatric intensive care units.
Did probiotics reduce ventilator-associated pneumonia?
Yes, the review found that probiotics significantly reduced the incidence of ventilator-associated pneumonia with a high level of certainty.
Were there any adverse events associated with probiotics?
No serious probiotic-associated adverse events were reported in the trials included in the review.